Immediate monitoring more than doubled the detection of clinically significant cardiac arrhythmias, rising from 9% in the standard care group to 22% in the monitoring group. ^[1] The ASPIRED trial, presented at ESC Congress 2026 and published in the New England Journal of Medicine, concluded that early ECG monitoring in the emergency department can transform care for patients with unexplained fainting. ^[2] The trial observed a 50% reduction in all-cause mortality at one year for patients receiving immediate monitoring (1.5%) compared to standard care (2.9%). ^[3] Immediate 14-day cardiac monitoring was associated with a reduction in all-cause death from 2.9% to 1.5% in the intervention group. ^[4] The ASPIRED trial found that immediate 14-day cardiac monitoring using the BodyGuardian Mini device did not reduce the mean number of patient-reported syncope episodes at one year compared to standard care. ^[5] Patients in the monitoring group received a diagnosis of their cardiac condition a median of 22 days earlier than those in the standard care group, who waited a median of 55 days. ^[6] Matthew James Reed, MD, of the Usher Institute, Edinburgh University in Scotland, reported that the incidence rate ratio for syncope episodes was 0.89 with a 95% confidence interval of 0.68-1.18. ^[7] Michele Brignole, MD, of IRCCS Istituto Auxologico in Milan, Italy, stated that the direct cause-effect relationship between arrhythmias and all-cause mortality remains uncertain and probably unlikely. ^[8]